Abstract
The influence of CYP enzymes and ABCB1 on treatment outcomes in schizophrenia: association of CYP1A2 activity with adverse effects
Highlights
Antipsychotic drugs are the mainstay of treatment for severe mental disorders such as schizophrenia and bipolar disorders
CYP1A2 was found to be associated with psychic side effects (P = 0.02), with variants predicting higher enzyme activity associated with lower adverse effects, and was the strongest predictor for this adverse effect of all the studied factors
Functional variants in CYP genes were associated with plasma level differences, with higher activity variants associated with lower plasma levels
Summary
Antipsychotic drugs are the mainstay of treatment for severe mental disorders such as schizophrenia and bipolar disorders. Plasma levels and all processes capable of affecting them may modify the dose-dependent fraction of the drug’s response These processes include transport across biological membranes, such as absorption and excretion, and metabolism. Individuals with greater metabolism may require higher doses, while those with lower metabolic rates might be more prone to the drugs’ adverse effects and need dose reduction[3,4,5,6,7]. With all these variables potential predictors of drug response, which of them, or combination of, is the best predictor of clinical endpoints, if at all
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
